arrow Log In to View Account     |          
UTASIP
UTASIP Logo
 

GOAL
To provide managed care and specialty pharmacists with up-to-date information regarding their role in managing patients with metastatic melanoma (MM).

TARGET AUDIENCE
This activity is designed for managed care and specialty pharmacists. No prerequisites required.

LEARNING OBJECTIVES
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • INTERPRET data that suggest a role for monoclonal antibodies in treatment of patients with MM.
  • EVALUATE methods for optimizing care of patients with MM while managing and/or preventing adverse events.
  • UNDERSTAND the specialty and managed care pharmacy implications of metastatic MM.

ACCREDITATION STATEMENT
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

CREDIT DESIGNATION STATEMENT
acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based educational activity will provide a statement for 1.5 contact hours credit (0.15 CEUs) and will be available for download following successful completion of the activity. Successful completion includes taking the pre-test, participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination one more time. ACPE Program # 0064-0000-10-207-H01-P.

This continuing pharmacy education activity was produced under the supervision of Glen E. Farr, PharmD, Associate Dean for Continuing Pharmacy Education, University of Tennessee College of Pharmacy.

The estimated time to complete this educational activity: 1.5 hours.

Release date: January 15, 2011; Expiration date: January 15, 2013.

FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

J. Aubrey Waddell, PharmD, FAPhA, BCOP (Chair)
Professor
University of Tennessee College of Pharmacy
Oncology Pharmacist
Blount Memorial Hospital
Maryville, Tennessee

Dr Waddell reports having no significant financial or advisory relationships with corporate organizations related to this activity.


Val R. Adams, PharmD, FCCP, BCOP
Associate Professor
University of Kentucky
Lexington, Kentucky
Dr Adams reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Nick Calla, RPh
Vice President, Trade Relations
Walgreens Specialty Pharmacy
Pittsburgh, Pennsylvania
Dr Calla reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Sheldon J. Rich, RPh, PhD
President, SJR Associates, LLC
Adjunct Clinical Assistant Professor, University of Michigan
Adjunct Assistant Professor, Wayne State University
Palm Beach Gardens, Florida
Dr Rich reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Van Anh Trinh, PharmD, BCOP
Clinical Pharmacy Specialist
MD Anderson Cancer Center
Division of Pharmacy
Melanoma and Sarcoma Medical Oncology
Houston, Texas
Dr Trinh reports having no significant financial or advisory relationships with corporate organizations related to this activity.

OFF-LABEL PRODUCT DISCUSSION
In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the participants of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

GRIEVANCE POLICY
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an educational activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

FEE INFORMATION
There is no fee for this educational activity.

TABLE OF CONTENTS
Pre-Assessment

Targeting Metastatic Melanoma (MM): Review of Current Guidelines and Practice

Immunomodulatory Approaches to MM

Managing Immune-Related Adverse Events in Patients Receiving Monoclonal Antibody Therapy for MM

Case Management for Patients with MM: Managed Care and Specialty Pharmacy Perspectives

Post-Assessment

This activity is supported by an educational grant from Bristol-Myers Squibb Company.

procced to pretest
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.